WLF Will Use FDA Notice On Circuit Court Ruling As Wedge To Reopen Case
This article was originally published in The Gray Sheet
Executive Summary
FDA's intention to use journal reprints distributed for off-label indications as evidence in misbranding enforcement actions violates the standing injunction on two "enduring materials" guidance documents, the Washington Legal Foundation contends.
You may also be interested in...
Disclaimers Do Not Remedy Content Violations – FDA Warning Letter
Providing disclaimers for material that promotes an uncleared or unapproved use does not remedy content violations, FDA's device center Promotion and Policy Staff emphasize in a Nov. 5 letter to Diomed
Disclaimers Do Not Remedy Content Violations – FDA Warning Letter
Providing disclaimers for material that promotes an uncleared or unapproved use does not remedy content violations, FDA's device center Promotion and Policy Staff emphasize in a Nov. 5 letter to Diomed
Testimonials Present Web Promoters With Unique Regulatory Pitfalls
Z'Strong International's Aug. 25 FDA warning letter for inappropriate use of testimonials in promoting its Z'Strong Bioelectrical Discharger on the company website is indicative of the agency's evolving policy on testimonials and Internet promotion.